Teligent
105 Lincoln Avenue
Buena
New Jersey
08310
United States
Tel: (856) 697-1441
Website: http://www.teligent.com/
About Teligent
We develop, manufacture and market pharmaceutical products for use by doctors and patients in the United States and Canada.
We are a dynamic group of about 200 employees based in New Jersey, Toronto, Montreal and Tallinn, Estonia. Our Product Development and Manufacturing complex is in Buena, New Jersey, approximately 45 minutes from Philadelphia.
Our Quality, Regulatory Affairs and Operations colleagues work closely with our Product Development team to achieve regulatory approval in the countries where we operate. Our Commercial team sells our portfolio of topical medicines and hospital-based sterile injectable products.
We are energized about what we are going to accomplish at Teligent today. We believe in taking ownership, driving execution, and making smart, quick decisions.
We are passionate about our science, and are committed to building a diverse pipeline of topical, injectable, complex and ophthalmic projects.It’s a powerful, uniting force that magnifies what we could do on our own. The Teligent spark empowers us to dream of a brighter future. To envision our work having a deeper impact on others’ lives. To build something that is bigger than ourselves.
Our journey is underway. It is driven by our culture, which is a reflection of our people.
NASDAQ: TLGT
84 articles about Teligent
-
Teligent Announces The Opening Of A Product Development Laboratory In Estonia
10/11/2016
-
Second Teligent Topical Product Approved By Health Canada
10/5/2016
-
Health Canada Approves First Teligent Topical Product
9/30/2016
-
Teligent To Present At Morgan Stanley Global Healthcare Conference On September 13, 2016
9/13/2016
-
Teligent Announces Health Canada Approval Of Three Baclofen Injection Products
8/25/2016
-
Teligent Announces Health Canada Approval Of Gentamicin Injection USP
8/23/2016
-
Teligent Announces Second Quarter 2016 Results
7/29/2016
-
Teligent To Hold Conference Call For 2nd Quarter 2016 Results
7/13/2016
-
Teligent Receives Two FDA Approvals For Topical Prescription Portfolio
7/8/2016
-
New Jersey's Teligent Increases Footprint by 200% in $50 Million Expansion
7/6/2016
-
Teligent To Present At JMP Securities Life Sciences Conference On June 21, 2016
6/21/2016
-
Teligent Announces FDA Approval Of Triamcinolone Acetonide Ointment USP, 0.1%
5/16/2016
-
Horizon Pharma Announces Settlement Of PENNSAID (Diclofenac Sodium Topical Solution) 2% W/W Patent Litigation With Teligent
5/13/2016
-
Teligent To Present At Bank of America Merrill Lynch Annual Health Care Conference On May 10, 2016
5/10/2016
-
Teligent To Present At Deutsche Bank 41st Annual Health Care Conference On May 4, 2016
5/3/2016
-
Teligent Announces First Quarter 2016 Results
4/29/2016
-
Teligent To Hold Conference Call For 1st Quarter 2016 Results
4/14/2016
-
Teligent Appoints Dr. Carole Ben-Maimon To Board Of Directors
3/31/2016
-
Teligent Announces Launch Of Cefotan (Cefotetan For Injection)
3/21/2016
-
Teligent To Present At Roth Capital Partners 28th Annual Growth Stock Conference On March 14, 2016
3/15/2016